Official Title
Predictors of Severe COVID-19 Outcomes (PRESCO)
Brief Summary

This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome (ARDS) and/or mortality, in patients presenting to the hospital with suspicion or diagnosis of COVID-19. We seek to understand whether there are early signatures that predict progression to ARDS, mortality, and/or other comorbid conditions. The duration of the study participation is approximately 3 months.

Active, not recruiting
Acute Respiratory Distress Syndrome
COVID-19
Eligibility Criteria

Inclusion Criteria:

- Participant or legally authorized representative willing and able to provide informed
consent

- Receiving care at a participating site

- Age 18 years old or older

- U.S. Resident

- Confirmed positive for COVID-19

- Willing and able to comply with all study procedures

Exclusion Criteria:

- Self reported pregnancy

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations

The University of Arizona
Tucson, Arizona, United States

Cedars-Sinai Medical Center
Los Angeles, California, United States

University of Illinois at Chicago
Chicago, Illinois, United States

Rush University Medical Center
Chicago, Illinois, United States

Weill Cornell Medical College
New York, New York, United States

University of Texas Southwestern Medical Center
Dallas, Texas, United States

Baylor College of Medicine
Houston, Texas, United States

Inova Health Care Services
Falls Church, Virginia, United States

Verily Life Sciences LLC
NCT Number
MeSH Terms
COVID-19
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury